Testim 1% testosterone gel for the treatment of male hypogonadism
- PMID: 15878382
- DOI: 10.1016/j.dinthera.2005.02.015
Testim 1% testosterone gel for the treatment of male hypogonadism
Abstract
Objective: The aim of this work was to review the pharmacokinetic and clinical profile of Testim (Auxilium Pharmaceuticals, Norristown, Pennsylvania) 1% gel formulation of testosterone for the treatment of male hypogonadism.
Methods: An English-language search of the medical literature was conducted using PubMed (1998-December 2004) and EMBASE (1998-December 2004). Search terms included ag(e)ing male, male hypogonadism, late-onset hypogonadism, testosterone, testosterone deficiency, testosterone therapy, testosterone replacement therapy, androgen therapy, testosterone gel, and Testim. Bibliographies of retrieved articles were also reviewed.
Results: Five published clinical studies were reviewed. Testim 50 mg showed clear pharmacokinetic differences from AndroGel (known as Testogel in Europe; Unimed Pharmaceuticals, Inc., and Solvay Pharmaceuticals, Inc., Marietta, Georgia) 1% testosterone gel 50 mg, with increases of 30% (90% CI, 8%-57%) and 47% (90% CI, 20%-79%) versus AndroGel, respectively, in AUC(0-24h) for total serum testosterone and free testosterone. In a 30-day study of 638 men with hypogonadism, sexual desire scores and sexual motivation scores increased after Testim treatment at weeks 1, 2, 3, and 4 (each, P < 0.001). During 12 months of treatment with Testim 50 or 100 mg in 371 men with hypogonadism, total serum testosterone levels were raised to and maintained within the normal adult range, lean body mass increased by 2.2 kg (P < 0.001), fat mass fell by 2.1% (P < 0.001), and bone mineral density increased by 2.58% (P < 0.001). Mean scores for sexual desire, performance, motivation, and spontaneous erections were all significantly higher (all, P < 0.001) than at baseline for all time points during 12-month studies of Testim. In 2 studies comparing Testim with different testosterone patches, treatment with the gel resulted in 10-fold fewer application-site reactions than either patch.
Conclusions: In men with hypogonadism, Testim gel raised and maintained serum testosterone levels to within the normal adult range, alleviated signs and symptoms associated with hypogonadism, and was well tolerated.
Similar articles
-
Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.Postgrad Med. 2013 Mar;125(2):30-9. doi: 10.3810/pgm.2013.03.2639. Postgrad Med. 2013. PMID: 23816769
-
Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men.Int J Impot Res. 2008 Mar-Apr;20(2):213-7. doi: 10.1038/sj.ijir.3901618. Epub 2007 Sep 27. Int J Impot Res. 2008. PMID: 17898800 Clinical Trial.
-
A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function.BJU Int. 2003 Jan;91(1):69-74. doi: 10.1046/j.1464-410x.2003.04016.x. BJU Int. 2003. PMID: 12614254 Clinical Trial.
-
Review of Testim gel.Expert Opin Pharmacother. 2006 Mar;7(4):477-84. doi: 10.1517/14656566.7.4.477. Expert Opin Pharmacother. 2006. PMID: 16503819 Review.
-
Testosterone replacement therapy for male hypogonadism: part III. Pharmacologic and clinical profiles, monitoring, safety issues, and potential future agents.Int J Impot Res. 2007 Jan-Feb;19(1):2-24. doi: 10.1038/sj.ijir.3901366. Epub 2005 Sep 29. Int J Impot Res. 2007. PMID: 16193074 Review.
Cited by
-
Transdermal testosterone replacement therapy in men.Drug Des Devel Ther. 2014 Jan 9;8:101-12. doi: 10.2147/DDDT.S43475. eCollection 2014. Drug Des Devel Ther. 2014. PMID: 24470750 Free PMC article. Review.
-
Pharmacokinetics of testosterone therapies in relation to diurnal variation of serum testosterone levels as men age.Andrology. 2022 Feb;10(2):209-222. doi: 10.1111/andr.13108. Epub 2021 Oct 8. Andrology. 2022. PMID: 34510812 Free PMC article. Review.
-
Targeting of androgen receptor in bone reveals a lack of androgen anabolic action and inhibition of osteogenesis: a model for compartment-specific androgen action in the skeleton.Bone. 2008 Sep;43(3):440-51. doi: 10.1016/j.bone.2008.04.026. Epub 2008 May 16. Bone. 2008. PMID: 18595795 Free PMC article.
-
The effects of testosterone on bone health in males with testosterone deficiency: a systematic review and meta-analysis.BMC Endocr Disord. 2020 Mar 7;20(1):33. doi: 10.1186/s12902-020-0509-6. BMC Endocr Disord. 2020. PMID: 32145741 Free PMC article.
-
The Effect of Testosterone Topical Solution in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel.Am J Mens Health. 2018 May;12(3):524-530. doi: 10.1177/1557988315609684. Epub 2015 Oct 5. Am J Mens Health. 2018. PMID: 26438471 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical